预防性口服葡萄糖凝胶与hPOD随机试验参与者2年随访时的神经感觉损害
该研究为多中心随机临床试验的前瞻性随访,纳入新西兰9个中心1359名有新生儿低血糖风险的晚期早产或足月儿,随机接受预防性40%葡萄糖凝胶或安慰剂凝胶0.5 mL/kg颊黏膜按摩。2年矫正年龄时,葡萄糖凝胶组与安慰剂组神经感觉损害风险无显著差异(20.8% vs 18.7%;aRR 1.13 [95%CI 0.90-1.41]),但葡萄糖凝胶组运动发育迟缓风险显著更高(2.5% vs 0.7%;aRR 3.79 [95%CI 1.27-11.32]),认知、语言和运动综合评分显著更低。
要点
- 预防性40%葡萄糖凝胶组与安慰剂组2年神经感觉损害风险无显著差异(20.8% vs 18.7%;aRR 1.13 [95%CI 0.90-1.41])。
- 葡萄糖凝胶组运动发育迟缓风险显著高于安慰剂组(2.5% vs 0.7%;aRR 3.79 [95%CI 1.27-11.32])。
- 葡萄糖凝胶组认知、语言和运动综合评分均显著低于安慰剂组(aMD分别为-1.30、-2.16、-1.40)。
核心结论
- 在有新生儿低血糖风险的晚期早产和足月儿中,出生1小时时预防性口服40%葡萄糖凝胶与安慰剂相比,2年矫正年龄时神经感觉损害风险无显著差异。
- 但研究可能效力不足,无法检测到小而可能具有临床重要性的风险增加,需要进一步研究包括更长期随访。
研究设计与样本
- 多中心随机临床试验的前瞻性随访,在18家澳大利亚和新西兰医院开展,时间为2015年1月至2019年5月。
- 纳入在新西兰9个中心随机化的有风险晚期早产或足月儿(n=1359),随访时间为2017年1月至2021年7月。
- 婴儿随机接受预防性40%葡萄糖凝胶(n=681)或安慰剂凝胶(n=678)0.5 mL/kg,出生1小时后颊黏膜按摩。
主要发现
- 符合条件婴儿中1197名(91%)完成评估(女性581名[49%])。
- 神经感觉损害在葡萄糖凝胶组与安慰剂组间无显著差异(20.8% vs 18.7%;未调整风险差[RD] 2.09% [95%CI -2.43%至6.60%];调整风险比[aRR] 1.13 [95%CI 0.90至1.41])。
- 认知和语言发育迟缓风险在葡萄糖凝胶组与安慰剂组间无显著差异(认知:7.6% vs 5.3%;RD 2.32% [95%CI -0.46%至5.11%];aRR 1.40 [95%CI 0.91至2.17];语言:17.0% vs 14.7%;RD 2.35% [95%CI -1.80%至6.50%];aRR 1.19 [95%CI 0.92至1.54])。
- 葡萄糖凝胶组运动发育迟缓风险显著高于安慰剂组(2.5% vs 0.7%;RD 1.81% [95%CI 0.40%至3.23%];aRR 3.79 [95%CI 1.27至11.32])。
- 葡萄糖凝胶组认知、语言和运动综合评分显著低于安慰剂组(调整平均差[aMD]分别为-1.30 [95%CI -2.55至-0.05]、-2.16 [95%CI -3.86至-0.46]、-1.40 [95%CI -2.60至-0.20]);其余27项次要结局组间无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究可能效力不足,无法检测到小而可能具有临床重要性的风险增加。
- 需要进一步研究包括更长期随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Prophylactic oral dextrose gel reduces neonatal hypoglycemia, but later benefits or harms remain unclear. OBJECTIVE: To assess the effects on later development of prophylactic dextrose gel for infants born at risk of neonatal hypoglycemia. DESIGN, SETTING, AND PARTICIPANTS: Prospective follow-up of a multicenter randomized clinical trial conducted in 18 Australian and New Zealand hospitals from January 2015 to May 2019. Participants were late preterm or term at-risk infants; those randomized in 9 New Zealand centers (n = 1359) were included and followed up between January 2017 and July 2021. INTERVENTIONS: Infants were randomized to prophylactic 40% dextrose (n = 681) or placebo (n = 678) gel, 0.5 mL/kg, massaged into the buccal mucosa 1 hour after birth. MAIN OUTCOMES AND MEASURES: The primary outcome of this follow-up study was neurosensory impairment at 2 years' corrected age. There were 44 secondary outcomes, including cognitive, language, and motor composite Bayley-III scores (mean [SD], 100 [15]; higher scores indicate better performance). RESULTS: Of eligible infants, 1197 (91%) were assessed (581 females [49%]). Neurosensory impairment was not significantly different between the dextrose and placebo gel groups (20.8% vs 18.7%; unadjusted risk difference [RD], 2.09% [95% CI, -2.43% to 6.60%]; adjusted risk ratio [aRR], 1.13 [95% CI, 0.90 to 1.41]). The risk of cognitive and language delay was not significantly different between the dextrose and placebo groups (cognitive: 7.6% vs 5.3%; RD, 2.32% [95% CI, -0.46% to 5.11%]; aRR, 1.40 [95% CI, 0.91 to 2.17]; language: 17.0% vs 14.7%; RD, 2.35% [95% CI, -1.80% to 6.50%]; aRR, 1.19 [95% CI, 0.92 to 1.54]). However, the dextrose gel group had a significantly higher risk of motor delay (2.5% vs 0.7%; RD, 1.81% [95% CI, 0.40% to 3.23%]; aRR, 3.79 [95% CI, 1.27 to 11.32]) and significantly lower composite scores for cognitive (adjusted mean difference [aMD], -1.30 [95% CI, -2.55 to -0.05]), language (aMD, -2.16 [95% CI, -3.86 to -0.46]), and motor (aMD, -1.40 [95% CI, -2.60 to -0.20]) performance. There were no significant differences between groups in the other 27 secondary outcomes. CONCLUSIONS AND RELEVANCE: Among late preterm and term infants born at risk of neonatal hypoglycemia, prophylactic oral 40% dextrose gel at 1 hour of age, compared with placebo, resulted in no significant difference in the risk of neurosensory impairment at 2 years' corrected age. However, the study may have been underpowered to detect a small but potentially clinically important increase in risk, and further research including longer-term follow-up is required. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12614001263684.
引用
- Edwards T, Alsweiler JM, Crowther CA, et al. Prophylactic Oral Dextrose Gel and Neurosensory Impairment at 2-Year Follow-up of Participants in the hPOD Randomized Trial. JAMA. 2022. PMID: 35315885. doi:10.1001/jama.2022.2363
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。